ImageneBio (IMA)
NASDAQ:IMA
Want to see IMA full AI Analyst Report?
IMA Stock Chart & Stats
$5.90
--
Market closed
$5.90
--
Day’s Range― - ―
52-Week Range$3.94 - $18.01
Previous CloseN/A
VolumeN/A
Average Volume (3M)69.52K
Market Cap
$63.87M
Enterprise Value$39.34M
Total Cash (Recent Filing)$75.78M
Total Debt (Recent Filing)$9.99M
Price to Earnings (P/E)―
Beta0.94
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,654,281
10 Day Avg. Volume58,561
30 Day Avg. Volume69,515
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.25
Price to Sales (P/S)42.01
P/FCF Ratio-0.70
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.10
Enterprise Value/Ebitda-0.78
Forecast
1Y Price Target
$2.00Price Target Upside-66.10% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest Leverage (low Debt-to-equity)Low debt-to-equity provides tangible financial flexibility for a pre-commercial biotech, reducing interest obligations and bankruptcy risk. This durable balance-sheet characteristic lengthens runway options and makes future capital raises less pressured by heavy fixed-charge burdens, aiding multi-quarter program execution.
$30M Private Warrant Financing Supports DevelopmentA secured $30M financing materially extends near-term runway and funds late-phase development and expanded indications for IMG-007. Financing tied to clinical progress reduces immediate dilution risk and allows the company to hit key development milestones that can de-risk programs over several quarters.
Experienced Finance Leadership AppointedBringing a seasoned biotech finance executive into the principal accounting role improves execution on regulatory reporting, budgeting and capital markets engagement. Durable leadership continuity reduces operational execution risk during clinical development and fundraising cycles over the next several quarters.
Bears Say
Revenue Fell To Zero; Pre-commercial StatusZero trailing revenue means the business is fully dependent on external funding rather than product cash flows; this structural feature increases execution risk and elongates the path to self-sufficiency, making multi-quarter planning highly sensitive to clinical success and financing markets.
Persistent Negative Operating And Free Cash FlowSustained cash burn requires recurring capital raises, constraining strategic optionality and increasing dilution risk. Even with improved pace since 2023, persistent negative free cash flow means management must prioritize financing and milestone pacing, which can delay expansion and prolong dependence on investors.
Shrinking Equity Base Increases Financing RiskA materially smaller equity cushion reduces the firm's ability to absorb clinical setbacks or expensive trials without dilutive financings. The ongoing erosion of equity heightens the probability that future capital raises will be required sooner, pressuring governance and long-term investor returns.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $3.94 and its highest was $18.01 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $63.87M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
Currently, no data Available
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Overvalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 10,654,281 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImageneBio?
Currently, no hedge funds are holding shares in IMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImageneBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (-66.10% Downside)
$2.00 (-66.10% Downside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.25%
12-Months-Change
Fundamentals
Return on Equity
-33.97%
Trailing 12-Months
Asset Growth
8.10%
Trailing 12-Months
Company Description
ImageneBio
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
IMA Stock 12 Month Forecast
Average Price Target
$2.00
▼(-66.10% Downside)
Technical Analysis
Ownership Overview
32.91% Insiders
2.77% Mutual Funds
37.84% Other Institutional Investors
23.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---